All questionsReal-world evidence: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer2 questions · 1 sourceReal-world evidenceWhat were TRODELVY real-world survival outcomes in previously treated metastatic TNBC?“A retrospective, observational cohort study assessed real-world clinical outcomes in patients with mTNBC treated with TRODELVY as 2L and later.5 Limitations: These EHR-derived, retrospective data were not powered for statistical analysis and should be considered descriptive only. The results require cautious interpretation and could represent chance findings. Data entry errors could have occurred. It is likely there are missing data.5” (opens the source at this quote in a new tab)CopyFlag“For the total population (N=230), the mPFS was 3.8 months (95% CI: 3.1–4.3) and the mOS was 10 months (95% CI: 8.3–11.1)5” (opens the source at this quote in a new tab)CopyFlag“Real-world OS rate (95% CI) 2L mTNBC (n=77) 3L+ mTNBC (n=153) Total (N=230) 12-month 51% (37–64) 35% (26–44) 40% (33–48) 24-month 32% (13–54) 20% (11–29) 23% (15–32)” (opens the source at this quote in a new tab)CopyFlag“From April 2020 to May 2022, 230 adult female patients with mTNBC were treated with TRODELVY in the 2L or later setting. 33% and 67% of patients received TRODELVY in the 2L and 3L+ settings, respectively.” (opens the source at this quote in a new tab)CopyFlagWhat TRODELVY side effects and dose changes were seen in real-world use?“A retrospective, observational cohort study assessed real-world clinical outcomes in patients with mTNBC treated with TRODELVY as 2L and later.” (opens the source at this quote in a new tab)CopyFlag“Real-world safety data (n=230)5 Limitations: Underreporting of AEs and dose modifications in physicians’ notes may have occurred with an unknown impact on the results.5 Dose reduction and interruptions were observed in 34% and 58% of all patients, with 26% and 39% due to toxicity, respectively; 7% discontinued TRODELVY due to toxicity5 Fatigue was reported in 45%, neutropenia in 33%, and diarrhea in 30% of patients5 Concomitant administration of G-CSF was observed in 58% of all patients, with most of these patients (99/134=74%) having received G-CSF with prior anticancer treatment5 15% of patients received G-CSF for the first time during treatment with TRODELVY. Among these patients, the median time from TRODELVY start to G-CSF use was 8.5 days (IQR: 8.0–29.0)” (opens the source at this quote in a new tab)CopyFlag